Skip to main content

Table 5 Best response after salvage PRRT

From: Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

Authors

patients n=

Number of PRRT cycles

Median Follow-Up [months]

CR/PR/MRa

SDb

PDc

This study

35

5–8

25

1 (3.1)

26 (81.6)

5 (15.3)

Sabet et al. [12]

33

5–8

23

7 (21.2)

14 (42.4)

11 (33.3)

van der Zwan et al. [14]

168

5–8

30.4

26 (15.5)

100 (59.5)

33 (19.6)

  1. aCR/PR/MR Complete/Partial/Minor Response, bSD Stable Disease, cPD Progressive Disease
  2. Data is presented as number (%) of patients. Assessment of best response was based on RECIST 1.1 in the current study and in [14] and on SWOG criteria in [12]; 3 and 9 patients were excluded in the current study and in [14], respectively